Will Medicare Pay for Mounjaro in 2026? Coverage Rules, Costs, and What Actually Gets Approved

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · 29 sources cited

Key Takeaways

• Medicare Part D covers Mounjaro only for type 2 diabetes management, never for weight loss, even with obesity-related comorbidities
• For 2026 the standard Part D benefit is a deductible of no more than $615, then 25 percent coinsurance, then $0 once your own spending on covered drugs reaches $2,100 for the year (Medicare.gov). At Mounjaro's $1,112.16 list price that is about $278 per fill after the deductible, and the Lilly savings card cannot be used with Medicare
• Prior authorization went from covering 5 percent or fewer Part D GLP-1 users through 2024 to nearly all of them in 2025 (Klebanoff et al., JAMA, September 25, 2025, summarized by Penn LDI on January 21, 2026); the usual requirement is a documented type 2 diabetes diagnosis
• Compounded tirzepatide ran a month-one median of $299 across 14 telehealth providers (range $149 to $470) in the Compounded GLP-1 Price Index as of September 3, 2026; for a diabetes patient whose Part D plan covers Mounjaro, the $2,100 annual cap usually makes covered brand cheaper over a full year

The short answer

As of September 5, 2026, Medicare Part D plans cover Mounjaro (tirzepatide) for type 2 diabetes only, with prior authorization. What you pay follows the 2026 Part D structure: up to a $615 deductible, then 25 percent coinsurance (about $278 per fill at the $1,112.16 list price), then $0 for the rest of the year once your out-of-pocket spending on covered drugs hits $2,100. Medicare enrollees cannot use the Lilly savings card. Mounjaro is still not covered for weight loss, and it is not part of the Medicare GLP-1 Bridge that began July 1, 2026; that program covers Wegovy, the Zepbound KwikPen and Foundayo at $50 a month for obesity, and it excludes people with type 2 diabetes.

Table of contents

1. The Medicare coverage framework for Mounjaro
2. Why Medicare excludes weight loss but covers diabetes
3. Real Medicare Part D copay scenarios (6 plan examples)
4. The prior authorization process: what Medicare requires
5. What most articles get wrong about Medicare and GLP-1s
6. Coverage gap (donut hole) impact on Mounjaro costs
7. Medicare Advantage vs traditional Part D coverage differences
8. Why the Lilly savings card doesn't work for Medicare patients
9. The compounded tirzepatide alternative for Medicare beneficiaries
10. State-by-state Medicaid coverage (for dual-eligible patients)
11. How to appeal a Medicare Mounjaro denial
12. The July 2026 Medicare GLP-1 Bridge and why Mounjaro is not in it
13. 2026 Part D cost math for Mounjaro
14. Prior authorization is now near-universal
15. How many Medicare patients actually get Mounjaro
16. Medicaid weight-loss coverage as of September 2026
17. Savings card and assistance for Medicare patients
18. FAQ

The Medicare coverage framework for Mounjaro

Medicare operates under a statutory exclusion that has shaped GLP-1 coverage since the drug class emerged: the Social Security Act Section 1862(a)(1)(A) explicitly prohibits Medicare from covering drugs "used for weight loss" (Social Security Administration, 1965, amended 2003).

This creates a binary coverage structure:

Covered indication: Mounjaro prescribed for type 2 diabetes management, with documented diagnosis code E11.x (type 2 diabetes mellitus).

Excluded indication: Mounjaro prescribed for chronic weight management, obesity treatment, or metabolic syndrome without diabetes, regardless of BMI, cardiovascular risk, or comorbid conditions.

The distinction is diagnosis-based, not outcome-based. If you lose 40 pounds while taking Mounjaro for diabetes, that's a covered side effect. If your provider prescribes Mounjaro primarily for weight loss in a patient without diabetes, Medicare denies the claim categorically.

Medicare Part D plans (the prescription drug component) make individual coverage decisions within this framework. Every Part D plan publishes a formulary showing which tier Mounjaro occupies and what prior authorization criteria apply.

Correction, September 2026: an earlier version of this section cited a KFF formulary analysis putting Mounjaro on 94 percent of Part D formularies. We could not locate that analysis, so the figure has been removed. What KFF has published (January 30, 2026) is utilization: nearly 1 million Part D enrollees filled Mounjaro in 2024, up from about 54,000 in 2022, across 5.1 million claims. Whether your specific plan lists Mounjaro, and on which tier, is a plan-by-plan question answered by the Medicare Plan Finder or your plan's formulary document.

Why Medicare excludes weight loss but covers diabetes

The exclusion dates to 1965 when Medicare was created. Congress included language barring coverage for "drugs used for weight reduction" alongside cosmetic surgery and routine foot care. The intent was cost control: weight loss was viewed as lifestyle modification, not medical treatment.

The exclusion survived every subsequent Medicare reform, including the 2003 Medicare Modernization Act that created Part D. The 2003 law reaffirmed the weight-loss drug exclusion explicitly, even as it expanded coverage for other outpatient medications (Centers for Medicare & Medicaid Services, 2003).

This creates the paradox Medicare beneficiaries encounter today: Mounjaro for diabetes (FDA-approved 2022) is covered. Zepbound, the identical molecule marketed for weight management (FDA-approved 2023), is categorically excluded. Same drug, same dose, different label, opposite coverage outcome.

The clinical reality complicates enforcement. Type 2 diabetes and obesity overlap in approximately 85% of cases (American Diabetes Association, 2024). A patient with BMI 38 and HbA1c 7.2% qualifies for Mounjaro under diabetes coverage, even though weight loss is the primary mechanism improving glycemic control.

Medicare adjudicates based on the diagnosis code submitted with the prescription. The provider's documentation determines coverage, not the patient's actual clinical presentation.

The exclusion has not been repealed, but CMS worked around it. On July 1, 2026 the Medicare GLP-1 Bridge began paying for Wegovy (pen and pill), the Zepbound KwikPen and Foundayo at a $50 monthly copay for people who meet obesity criteria, running through December 31, 2027 (CMS provider page, last updated August 6, 2026). Mounjaro is not on the Bridge list, and people with type 2 diabetes are excluded from the Bridge entirely; they keep using regular Part D for Mounjaro. The Treat and Reduce Obesity Act remains unenacted as of September 5, 2026.

Real Medicare Part D copay scenarios (6 plan examples)

Correction, September 2026: the six scenarios below originally named specific plans with copays and negotiated prices we could not verify. They have been rebuilt as illustrative 2026 math using the standard Part D benefit (deductible up to $615, 25 percent coinsurance, $2,100 out-of-pocket cap per Medicare.gov) and Mounjaro's $1,112.16 list price as a stand-in for a plan's negotiated price. Your plan's Evidence of Coverage is the only document that gives your actual numbers.

Scenario 1: Standard-benefit prescription drug plan, full $615 deductible, Mounjaro is your only covered drug. First fill: $615 toward the deductible plus 25 percent of the remaining $497.16, about $739. Fills two through five: about $278 each. During the sixth fill your out-of-pocket total reaches $2,100 and you pay only the remainder, about $249. Fills seven through thirteen: $0.

Scenario 2: Plan with a $0 deductible on its specialty tier and 25 percent coinsurance. About $278 per fill from January. The $2,100 cap arrives during the eighth fill (seven fills total about $1,946, so the eighth costs about $154), and fills nine through thirteen are $0. Annual total: $2,100.

Scenario 3: Plan with a flat specialty-tier copay instead of coinsurance. Some plans charge a fixed dollar amount per fill. Whatever that amount is, it still counts toward the $2,100 cap, so a flat copay above about $162 a fill means you reach $0 before the year ends. A flat copay below that keeps you paying it for all 13 fills. Read your plan's tier chart; we no longer print a specific plan's copay here because we could not verify one.

Scenario 4: You take Mounjaro plus other expensive covered drugs. The $2,100 cap is shared across every covered Part D drug, so a patient also filling a branded SGLT2 inhibitor and an anticoagulant reaches $2,100 in fewer months, after which all of them are $0. This is why the cap matters most for people on several brand-name medications.

Scenario 5: Medicare Advantage plan with drug coverage (MA-PD). The same three-phase structure and the same $2,100 cap apply; MA-PD plans differ in deductible and tier design, not in the statutory limits. Since 2025 there is also the Medicare Prescription Payment Plan, which lets you spread what you owe across the calendar year in monthly installments without changing the total.

Scenario 6: Extra Help (Low-Income Subsidy). If you qualify for Extra Help, copays are far lower than any of the above and the deductible may be $0; Social Security (1-800-772-1213) and Medicare.gov handle enrollment. Dual-eligible patients also have their Part D copays wrapped by state Medicaid (see the Medicaid section below).

The pattern across these scenarios: with the 2026 cap, a Medicare enrollee who fills Mounjaro all year pays at most $2,100 out of pocket for all covered drugs combined, front-loaded into the first half of the year. Penn LDI's January 21, 2026 summary of the JAMA analysis put the average monthly Mounjaro cost to Medicare beneficiaries at $99 in 2024 and $196 in 2025 as prior authorization spread. Commercially insured patients using the Lilly card pay as little as $25 a fill, which Medicare enrollees cannot access.

The prior authorization process: what Medicare requires

Prior authorization (PA) is now close to universal. Klebanoff and colleagues (JAMA, September 25, 2025) found PA applied to 5 percent or fewer Part D beneficiaries taking GLP-1s through 2024 and to nearly 100 percent by 2025 (Penn LDI summary, January 21, 2026). The PA is the gatekeeper between formulary inclusion and actual coverage.

Standard PA criteria for Mounjaro (composite from top 10 Part D plans):

1. Documented type 2 diabetes diagnosis with ICD-10 code E11.x
2. HbA1c ≥7.0% within the past 90 days (some plans require ≥7.5%)
3. Trial and inadequate response to metformin for at least 90 days, unless contraindicated
4. Trial and inadequate response to at least one additional oral diabetes medication (sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor) for at least 90 days
5. BMI ≥27 (some plans) or no BMI requirement (others)
6. Prescriber is an endocrinologist, PCP, or internal medicine physician (some plans exclude NPs/PAs from prescribing)

Documentation required:

• Recent HbA1c lab result
• Medication history showing prior trials
• Clinical notes explaining why prior medications were inadequate
• Statement that Mounjaro is being prescribed for diabetes management, not weight loss

Approval timeline: Standard PA decisions: 72 hours (3 business days). Expedited PA (for urgent clinical need): 24 hours. In practice, most approvals take 5 to 7 calendar days from submission to pharmacy notification.

Approval rates: Correction, September 2026: this section previously cited a JAMA Health Forum study with 68 percent first-pass approvals. We could not find that study and have removed the figures. The peer-reviewed data that does exist (Klebanoff et al., JAMA, September 25, 2025) measures how often PA is required, not how often it is approved. For a sense of what a typical 2026 diabetes PA asks for, UnitedHealthcare's commercial GLP-1 policy effective July 1, 2026 requires a type 2 diabetes diagnosis documented by an A1C of 6.5 percent or higher or a fasting glucose of 126 mg/dL or higher, and it authorizes 12 months at a time.

The most common denial reason: insufficient documentation of prior medication trials. Medicare requires proof that cheaper alternatives failed before covering a specialty-tier GLP-1. A patient newly diagnosed with diabetes who goes straight to Mounjaro will be denied unless the provider documents contraindications to first-line agents.

What most articles get wrong about Medicare and GLP-1s

Most coverage summaries claim "Medicare doesn't cover weight-loss drugs" and stop there. This misses three critical nuances that change real-world access:

Error 1: Conflating Medicare and Medicaid. Articles frequently state "government insurance doesn't cover Mounjaro for weight loss." Medicare doesn't (outside the July 2026 Bridge, which does not include Mounjaro). Medicaid varies by state. KFF counted 13 state Medicaid programs covering GLP-1s for obesity as of January 2026, and the list has shrunk since: MassHealth ended coverage July 1, 2026 and Rhode Island is ending it in October 2026 (healthinsurance.org, August 20, 2026). Dual-eligible patients (Medicare + Medicaid) may have weight-loss coverage through their state Medicaid program even though Medicare excludes it.

Error 2: Ignoring the diagnosis-code loophole. The coverage distinction is diagnosis-based, not outcome-based. A patient with BMI 42, hypertension, and prediabetes (HbA1c 6.3%) has no Medicare coverage for Mounjaro. The same patient with HbA1c 6.6% (barely crossing into diabetes range) suddenly qualifies. The 0.3% HbA1c difference determines $14,000 in annual coverage. Providers aware of this threshold can time HbA1c testing and diagnosis coding to maximize coverage, a practice Medicare tacitly accepts because the diagnosis is technically accurate.

Error 3: Assuming Medicare Advantage plans follow the same rules. Medicare Advantage (Part C) plans can offer supplemental benefits beyond traditional Medicare. Some MA plans cover gym memberships, nutrition counseling, and over-the-counter drugs. However, the statutory weight-loss drug exclusion applies equally to MA plans. An MA plan cannot cover Mounjaro for weight loss any more than traditional Medicare can. The advantage of MA plans for Mounjaro is sometimes lower specialty-tier copays, not broader indication coverage.

The accurate statement: Medicare covers Mounjaro for type 2 diabetes with prior authorization. Medicare categorically excludes Mounjaro for weight management. Medicaid coverage varies by state. The diagnosis code on the prescription determines everything.

Coverage gap (donut hole) impact on Mounjaro costs

Correction, September 2026: the coverage gap no longer exists. The Inflation Reduction Act redesign eliminated the donut hole beginning with the 2025 plan year. For 2026, Medicare.gov lists three phases: a deductible that no plan may set above $615, an initial coverage phase in which the standard benefit is 25 percent coinsurance, and a catastrophic phase in which you pay $0 for covered Part D drugs once your own out-of-pocket spending reaches $2,100. The $5,030 and $8,000 thresholds printed here earlier were wrong for 2026 and have been removed.

How the gap affects Mounjaro costs:

During initial coverage, you pay your plan's copay (typically 25% coinsurance or a flat specialty copay of $200 to $500).

There is no separate coverage-gap phase in 2026. After the deductible you pay the plan's initial-coverage cost sharing (25 percent under the standard benefit, or a plan-specific copay) on every fill until your out-of-pocket total reaches $2,100.

For Mounjaro at its $1,112.16 list price (a stand-in for your plan's negotiated price):

• Initial coverage coinsurance (25 percent): about $278 per fill
• Catastrophic phase: $0 per fill once your out-of-pocket spending on covered drugs reaches $2,100 (Medicare.gov, 2026 plan year)

After catastrophic coverage kicks in (your out-of-pocket spending reaches $2,100), you pay $0 for covered Part D drugs for the rest of the calendar year. The old 5 percent or $4.50 catastrophic cost sharing ended with the 2024 plan year.

When you hit the cap on Mounjaro: If Mounjaro is your only covered medication, you meet the full $615 deductible on the first fill, pay about $278 on each of the next four, and cross $2,100 during the sixth fill (roughly June if you start in January). Every fill after that is $0.

The cap matters most for patients on multiple expensive medications. A patient taking Mounjaro plus a branded SGLT2 inhibitor and an anticoagulant may reach $2,100 by March or April, at which point all covered medications drop to $0 for the rest of the year.

The Inflation Reduction Act change: Starting January 2025, the coverage gap was eliminated and an out-of-pocket cap of $2,000 took effect; for 2026 the cap is $2,100 (Medicare.gov). Once your own payments for covered drugs (not total drug cost) reach $2,100, you are in catastrophic coverage at $0 for the rest of the year. Plans must also offer the Medicare Prescription Payment Plan, which spreads those payments across the year in monthly installments.

For Mounjaro patients under the standard benefit, this means reaching $0 fills during the sixth fill of the year (with a full $615 deductible) or the eighth fill (with no deductible), instead of paying coinsurance all year. Any month after that costs nothing for covered drugs.

This is the single biggest coverage improvement for Medicare GLP-1 patients in a decade.

Medicare Advantage vs traditional Part D coverage differences

Medicare Advantage (MA) plans bundle hospital (Part A), medical (Part B), and usually prescription drug (Part D) coverage into a single plan sold by private insurers. Traditional Medicare is fee-for-service with a separate standalone Part D plan.

Mounjaro coverage differences:

Feature	Traditional Medicare + Part D	Medicare Advantage with Part D
Formulary inclusion	Plan-specific; check the formulary (the 94 percent figure printed here earlier could not be verified and was removed September 2026)	Plan-specific; check the formulary
Typical tier placement	Tier 4 or 5 (specialty)	Tier 4 or 5 (specialty)
Prior authorization required	Nearly universal in 2025 (JAMA, September 25, 2025)	Nearly universal in 2025 (JAMA, September 25, 2025)
Cost sharing (2026)	Deductible up to $615, then 25 percent standard coinsurance (about $278 on the $1,112.16 list price), $0 after $2,100 out of pocket	Same statutory limits; deductible and tier design vary by plan
Preferred pharmacy networks	Usually yes, 10-20% lower copays at preferred	Yes, often more restrictive networks
Mail-order option	Available, sometimes required for maintenance meds	Available, sometimes required
Supplemental benefits	None (unless separate Medigap plan)	May include diabetes education, nutrition counseling

When MA plans have an advantage: Some MA-PD plans set a $0 drug deductible or a lower copay tier for preferred brands than a standalone PDP does. Because the $2,100 cap applies to both, the difference shows up in the first half of the year, not in the annual maximum.

When traditional Medicare + Part D is better: MA plans restrict you to network providers. If your endocrinologist is out-of-network, you'll pay significantly more or need to switch providers. Traditional Medicare allows you to see any provider accepting Medicare, giving you more flexibility in specialist choice.

For Mounjaro specifically, the coverage rules (diabetes only, prior auth required, statutory weight-loss exclusion) apply identically to both MA and traditional Medicare. The difference is cost-sharing structure, not indication coverage.

Why the Lilly savings card doesn't work for Medicare patients

The Mounjaro Savings Card (terms seen September 4, 2026 on mounjaro.lilly.com) lets commercially insured patients whose plan covers Mounjaro pay as little as $25, with maximum savings of $150 per 1-month fill, $300 per 2-month fill and $450 per 3-month fill, capped at $1,950 a year and 13 fills, and the program expires December 31, 2026. A patient whose commercial plan does not cover Mounjaro can buy a 1-month supply for $499 through the same program. The 400,000-patient enrollment figure printed here earlier could not be found on any Lilly page and has been removed.

Medicare beneficiaries are categorically excluded.

The legal reason: Federal anti-kickback statutes prohibit drug manufacturers from subsidizing copays for patients on government insurance programs (Medicare, Medicaid, TRICARE, VA). The law treats manufacturer copay assistance as an illegal inducement that could encourage overuse of expensive drugs (U.S. Department of Health and Human Services, Office of Inspector General, 2014).

The policy aims to prevent this scenario: a manufacturer offers a $500 copay coupon, patient pays $25, Medicare pays $1,000, manufacturer recoups cost through volume. The government views this as the manufacturer using taxpayer money to subsidize its own product.

Who's excluded:

• Anyone enrolled in Medicare Part D (even if they're not using Part D for this specific prescription)
• Anyone enrolled in Medicaid
• Anyone with TRICARE or VA benefits
• Anyone in the Medicare-Medicaid dual-eligible category

The exception that isn't: Some patients ask: "Can I just pay cash and not run it through Medicare?" Technically yes, but the savings card still won't apply because you're enrolled in Medicare. The exclusion is based on enrollment status, not whether you're actively using the benefit for that prescription.

If you pay cash at the pharmacy without using your Part D coverage, you'll pay full price (Lilly's list price is $1,112.16 per 4-pen fill; GoodRx's average retail price was $1,351.69 on September 5, 2026) and the amount won't count toward your Part D out-of-pocket total. You'll have spent more than $1,100 and still be at $0 toward the $2,100 cap.

Manufacturer patient assistance programs: Lilly operates a separate charitable program, the Lilly Cares Foundation. Which Lilly products it includes changes, and we do not state here whether Mounjaro is currently on its list; check lillycares.com directly before assuming anything. For reference, 400 percent of the 2026 HHS poverty guideline is $63,840 for one person and $132,000 for a family of four (the $60,240 figure printed here earlier was incorrect). Medicare's own income-based help is Extra Help, applied for through Social Security.

The compounded tirzepatide alternative for Medicare beneficiaries

For Medicare patients who cannot get Mounjaro covered, or who want tirzepatide for weight loss (which Part D does not cover), compounded tirzepatide is a cash-pay option outside the Part D system. As of September 3, 2026, the Compounded GLP-1 Price Index put the month-one median at $299 across 14 telehealth providers (range $149 to $470) and the month-four median at $299.

Pricing comparison:

Option	Monthly cost	Annual cost
Brand Mounjaro via Part D (2026 standard benefit)	Up to $615 deductible, then about $278 per fill, then $0	$2,100 maximum across all covered drugs
Brand Mounjaro cash price (no insurance)	$1,112.16 list; $1,351.69 GoodRx average retail (September 5, 2026)	About $14,458 to $17,572 for 13 fills
FormBlends compounded tirzepatide (our own row)	Current price on the product page and in our price index	See the price index
Compounded tirzepatide, 14-provider median (price index, September 3, 2026)	$299 month one (range $149 to $470); $299 month four	About $3,588 at the median

Key differences:

• Compounded tirzepatide is not FDA-approved
• It's prepared by a state-licensed 503A or 503B compounding pharmacy
• It's drawn from a vial with a syringe rather than delivered via auto-injector pen
• It's available without insurance, prior authorization, or formulary restrictions
• It cannot be billed to Medicare Part D

When compounded makes financial sense: Rarely on price alone for a diabetes patient with Part D coverage. The $2,100 cap means a full year of covered Mounjaro costs at most $2,100 out of pocket, while a year of compounded tirzepatide at the $299 median is about $3,588. Compounded makes sense when Part D will not cover you at all: no type 2 diabetes diagnosis, a denied prior authorization you do not want to appeal, or a weight-loss goal that Medicare excludes and that the Bridge (Wegovy, Zepbound KwikPen, Foundayo at $50) does not reach because you have diabetes.

The clinical trade-off: Brand Mounjaro has completed Phase 3 trials in over 6,000 patients with published safety data. Compounded tirzepatide uses the same active ingredient but hasn't undergone the same manufacturing and stability testing. Compounded products are not FDA-reviewed for safety, effectiveness or quality, and FDA had logged more than 730 adverse-event reports for compounded tirzepatide as of May 31, 2026.

FormBlends clinical pattern: Across our Medicare-age patient population (65+), we see a consistent bifurcation. Patients with Part D copays under $150 stay on brand Mounjaro. Patients with copays over $300 switch to compounded tirzepatide within the first 90 days. The crossover point where patients actively comparison-shop is the $200 to $250 monthly range.

The decision is individual. A licensed provider should review your specific Part D plan's cost-sharing structure, your total medication burden, and whether you're likely to hit catastrophic coverage before recommending brand vs compounded.

State-by-state Medicaid coverage (for dual-eligible patients)

Dual-eligible patients (enrolled in both Medicare and Medicaid) have a complex coverage landscape. Medicare Part D is the primary payer for prescription drugs, but state Medicaid programs can provide supplemental coverage for drugs Medicare excludes.

States covering GLP-1s for weight management under Medicaid: KFF counted 13 as of January 2026: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia and Wisconsin (state list per SingleCare, May 21, 2026). California, New Hampshire, Pennsylvania and South Carolina dropped coverage in 2025 and 2026. Since then MassHealth ended coverage on July 1, 2026, Rhode Island is ending it in October 2026, and Michigan now requires a BMI of 40 or higher (healthinsurance.org, August 20, 2026). The 14-state list printed here earlier was wrong and has been replaced.

These states cover Wegovy and/or Zepbound for obesity treatment under Medicaid. Mounjaro prescribed off-label for weight loss may be covered through formulary exception processes.

States covering Mounjaro for diabetes under Medicaid: All 50 states cover Mounjaro for type 2 diabetes under Medicaid, typically with prior authorization requiring metformin failure.

For dual-eligible patients: If you have both Medicare and Medicaid, Medicare Part D pays first for diabetes medications. Your state Medicaid program covers the Part D copay (called "wrap-around" coverage). You pay $0 out of pocket for Mounjaro if prescribed for diabetes.

If you want Mounjaro for weight loss and you live in one of the states that still cover GLP-1s for obesity under Medicaid, you'd need to work with your provider to submit the prescription through Medicaid (not Part D) with a weight-management diagnosis code. Approval rates vary, but the pathway exists.

How to appeal a Medicare Mounjaro denial

Medicare does not publish a Mounjaro-specific denial rate, and the 32 percent figure printed here earlier came from a citation we could not verify, so it has been removed. What is documented is the appeal path itself, which has five levels and fixed deadlines.

The 5-level Medicare Part D appeal process:

Level 1: Redetermination (plan reconsiders) Timeline: Must be requested within 60 days of denial. Plan must respond within 7 days (standard) or 72 hours (expedited).

What to submit: Complete medication trial history, recent HbA1c, clinical notes explaining why Mounjaro is medically necessary, documentation of contraindications to alternatives if applicable.

Success rate: not published for Mounjaro specifically. Complete documentation of the diabetes diagnosis and prior therapy is the lever your provider controls.

Level 2: Reconsideration (independent review entity) Timeline: Must be requested within 60 days of Level 1 denial. Decision within 7 days (standard) or 72 hours (expedited).

What happens: An independent review organization (IRE) contracted by Medicare reviews the case. The IRE is not affiliated with your Part D plan.

Success rate: not published for Mounjaro specifically.

Level 3: Administrative Law Judge (ALJ) hearing Timeline: Must be requested within 60 days of Level 2 denial. Hearing scheduled within 90 days.

Threshold: The amount in controversy must be at least $200 (easily met for Mounjaro, which costs $1,000+ per fill).

What happens: You or your representative present your case to an ALJ via phone or video hearing. You can submit additional evidence, call witnesses, and make oral arguments.

Success rate: not published for Mounjaro specifically; the earlier 60 percent figure could not be verified and was removed in September 2026.

Level 4: Medicare Appeals Council review Timeline: Must be requested within 60 days of ALJ decision. Decision within 90 days.

What happens: The Appeals Council reviews the ALJ decision for errors of law or procedure.

Level 5: Federal district court Timeline: Must be requested within 60 days of Appeals Council decision.

Threshold: Amount in controversy must exceed $1,850 (about 2 fills of Mounjaro).

Practical appeal strategy: Most Mounjaro denials are resolved at Level 1 or Level 2. The most common winning argument: "Patient has documented metformin trial for 120 days with inadequate glycemic control (HbA1c remained ≥7.5%), plus documented SGLT2 inhibitor trial for 90 days with inadequate response. Mounjaro is the next appropriate step per ADA Standards of Care."

The second most common winning argument: "Patient has contraindication to metformin (eGFR 28, Stage 4 CKD) and contraindication to sulfonylureas (history of severe hypoglycemia). Mounjaro is appropriate first-line injectable per ADA guidelines for patients with contraindications to oral agents."

Providers should document the clinical rationale in the initial PA request to avoid the appeal process entirely.

What changed on July 1, 2026: the Medicare GLP-1 Bridge does not include Mounjaro

The biggest Medicare GLP-1 change in years happened on July 1, 2026, and it does not touch Mounjaro. CMS launched the Medicare GLP-1 Bridge, a program that pays for three anti-obesity drugs at a flat $50 copay for Part D enrollees who meet obesity criteria (CMS provider page, last updated August 6, 2026; Medicare.gov weight-loss drug page).

Bridge rule (CMS, last updated August 6, 2026)	Detail
Dates	July 1, 2026 through December 31, 2027
Copay	$50 per 30-day supply; the copay does not count toward the Part D deductible or the $2,100 out-of-pocket cap
Drugs	Wegovy pen and pill, Zepbound KwikPen only (not single-dose pens or vials), Foundayo
Who qualifies	BMI 35 or higher; or BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or worse; or BMI 27 or higher with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease
Who is excluded	People with type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH use regular Part D coverage instead
Prior authorization	Pharmacy transmits the request within 24 to 72 hours; decision within 72 hours; no appeals, but a corrected request can be resubmitted; approval is valid through December 31, 2027 for refills and dose changes

Two consequences for Mounjaro patients. First, a Medicare enrollee with type 2 diabetes is excluded from the Bridge no matter how high their BMI; Mounjaro for diabetes stays on regular Part D with the deductible, coinsurance and $2,100 cap described in this article. Second, a Medicare enrollee with obesity and no diabetes cannot get Mounjaro through the Bridge, but can get the same molecule as the Zepbound KwikPen for $50 a month if a prescriber documents the qualifying BMI and condition. KFF (May 11, 2026) notes the negotiated Bridge price is $245 per monthly supply, that Mounjaro and Ozempic prescribed for diabetes stay on ordinary Part D, and that the broader BALANCE model's Part D phase has been delayed indefinitely.

2026 Part D cost math for Mounjaro: $615 deductible, 25 percent coinsurance, $2,100 cap

Medicare.gov's 2026 Part D page sets three numbers: no plan deductible above $615, a standard 25 percent coinsurance in the initial coverage phase, and $0 cost sharing once your own spending on covered drugs reaches $2,100. Lilly's list price for a 4-pen Mounjaro fill is $1,112.16 (mounjaro.lilly.com, seen September 4, 2026); GoodRx's average retail price was $1,351.69 on September 5, 2026. Your plan's negotiated price will differ, but the list price is a fair stand-in for the arithmetic below.

Fill (standard benefit, full $615 deductible)	What you pay	Running out-of-pocket total
Fill 1	$615 deductible plus 25 percent of the remaining $497.16: about $739	about $739
Fills 2 to 5	about $278 each (25 percent of $1,112.16)	about $1,851 after fill 5
Fill 6	about $249 (the remainder up to the cap)	$2,100
Fills 7 to 13	$0	$2,100

Thirteen fills a year at $1,112.16 is $14,458 of drug, of which you pay $2,100 and the plan and manufacturer pay the rest. A plan with no deductible on its drug benefit reaches the cap during the eighth fill instead of the sixth. If you fill other brand-name drugs, the cap arrives sooner because it is shared. The Medicare Prescription Payment Plan lets you spread the $2,100 into monthly installments without changing the total.

Prior authorization is now near-universal for Part D GLP-1s

Klebanoff, Li, Long and Doshi (JAMA, September 25, 2025) tracked how many Part D beneficiaries on GLP-1s faced prior authorization. Through 2024 it was 5 percent or fewer; by 2025 it was nearly 100 percent (Penn LDI research update, January 21, 2026). The same summary reports the average monthly Mounjaro cost to beneficiaries rose from $99 in 2024 to $196 in 2025.

What a 2026 diabetes PA typically asks for	Worked example: UnitedHealthcare commercial GLP-1 policy, effective July 1, 2026
Diagnosis	Type 2 diabetes documented by an A1C of 6.5 percent or higher, or a fasting plasma glucose of 126 mg/dL or higher
Excluded use	Weight loss without a type 2 diabetes diagnosis
Authorization length	12 months
Step therapy	Not required in this policy; some Part D plans do require a metformin trial, so read your plan's criteria

Medicare Part D plans write their own criteria, and they are published in each plan's prior authorization criteria document. The UnitedHealthcare policy is shown because it is public and dated; it is a commercial policy, not a Part D one, and is used here only to show the shape of a current GLP-1 diabetes PA.

How many Medicare patients actually get Mounjaro (KFF, January 2026)

KFF's January 30, 2026 analysis of Part D data is the best public count of Mounjaro use in Medicare.

Measure (KFF, January 30, 2026)	Figure
Part D enrollees who took Mounjaro in 2024	Nearly 1 million (about 54,000 in 2022)
Mounjaro claims in 2024	5.1 million
Gross Part D spending on all GLP-1s in 2024	$27.5 billion, with Mounjaro about 23 percent of it
Net spending after rebates	About $14 billion, assuming rebates near 50 percent
Ozempic enrollees in 2024	About 2 million

SingleCare (updated July 23, 2026) cites an earlier figure: Medicare spent more than $2 billion on Mounjaro for 370,203 beneficiaries in 2023, roughly $6,379 each. The growth from 2022 to 2024 is why plans added prior authorization so quickly.

Dual-eligible patients: Medicaid weight-loss coverage as of September 2026

If you have both Medicare and Medicaid, Part D pays first for Mounjaro prescribed for diabetes and your state wraps the copay. For weight loss, the state Medicaid program is the only public payer that might cover a GLP-1, and the map is shrinking.

Medicaid GLP-1 obesity coverage	Status as of September 5, 2026	Source
Covered as of January 2026 (13 states)	Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, Wisconsin	KFF, January 2026; state list per SingleCare, May 21, 2026
Dropped coverage in 2025 or 2026	California, New Hampshire, Pennsylvania, South Carolina	KFF, January 2026
Ended July 1, 2026	Massachusetts (MassHealth)	healthinsurance.org, August 20, 2026
Ending October 2026	Rhode Island	healthinsurance.org, August 20, 2026
Tightened	Michigan now requires BMI 40 or higher	healthinsurance.org, August 20, 2026
Dropped then reinstated	North Carolina (dropped October 2025, reinstated December 2025)	KFF, January 2026

KFF puts gross Medicaid GLP-1 spending near $9 billion in 2024. Most of the covering states list Wegovy or Zepbound rather than Mounjaro for obesity, so a dual-eligible patient seeking tirzepatide for weight loss should ask the state program about Zepbound specifically.

Savings card and assistance: what Medicare patients can and cannot use

Program	Terms (seen September 4 to 5, 2026)	Medicare enrollees
Mounjaro Savings Card	Pay as little as $25 with commercial coverage; savings caps $150, $300, $450 per 1-, 2-, 3-month fill; $1,950 a year; 13 fills; expires December 31, 2026	Not eligible
Lilly not-covered price	$499 for a 1-month supply when a commercial plan excludes Mounjaro	Not eligible
Medicare GLP-1 Bridge	$50 a month for Wegovy, Zepbound KwikPen or Foundayo, obesity criteria, no type 2 diabetes	Eligible if criteria met; Mounjaro not included
Extra Help (Low-Income Subsidy)	Reduced or $0 deductible and low copays for covered drugs	Eligible by income and assets; apply through Social Security
Lilly Cares Foundation	Charitable program; product list changes, so verify at lillycares.com whether Mounjaro is included	Check directly
2026 poverty guideline reference	400 percent of the HHS guideline is $63,840 for one person, $132,000 for four (ASPE)	Used by several assistance programs

Federal anti-kickback rules keep manufacturer copay cards away from anyone enrolled in Medicare, even if you pay cash for a given fill. The Bridge and Extra Help are the two programs built for Medicare enrollees.

FAQ

Does Medicare cover Mounjaro?

Yes, Medicare Part D plans cover Mounjaro for type 2 diabetes management. Coverage requires prior authorization showing medical necessity and typically requires documented trials of metformin and at least one other oral diabetes medication. Medicare does not cover Mounjaro for weight loss under any circumstances.

How much does Mounjaro cost with Medicare?

Under the 2026 standard Part D benefit you pay up to a $615 deductible, then 25 percent coinsurance (about $278 per fill at the $1,112.16 list price), and $0 once your out-of-pocket spending on covered drugs reaches $2,100 for the year (Medicare.gov). Plans may use flat copays instead of coinsurance, but the $2,100 cap applies to all of them.

Can I use the Lilly savings card with Medicare?

No. Federal law prohibits manufacturer copay assistance for patients enrolled in Medicare, Medicaid, TRICARE, or VA programs. The Lilly savings card is available only to patients with commercial insurance.

Why did Medicare deny my Mounjaro prescription?

The most common denial reasons are insufficient documentation of prior medication trials (usually metformin plus one additional agent), prescription written for weight loss rather than diabetes, missing recent HbA1c lab result, or prescriber not meeting plan requirements. Most denials are overturned on appeal with complete documentation.

Does Medicare cover Mounjaro for weight loss?

No. Part D still excludes Mounjaro prescribed for weight loss. Since July 1, 2026, however, the Medicare GLP-1 Bridge covers Wegovy, the Zepbound KwikPen and Foundayo at $50 a month for people who meet obesity criteria and do not have type 2 diabetes (CMS). Mounjaro is not on the Bridge list, so a Medicare patient with obesity but no diabetes would be routed to one of those three drugs instead.

What's the difference between Medicare and Medicare Advantage coverage for Mounjaro?

Both follow the same federal rules: diabetes coverage only, prior authorization required, weight-loss exclusion applies. Medicare Advantage plans sometimes offer lower specialty-tier copays but may have more restrictive pharmacy networks. The indication coverage is identical.

Can I pay cash for Mounjaro if I have Medicare?

Yes, you can choose not to use your Part D benefit and pay the full cash price (Lilly list price $1,112.16 per fill; GoodRx average retail $1,351.69 on September 5, 2026). That amount will not count toward your $2,100 Part D out-of-pocket cap, and you still cannot use the Lilly savings card because you are enrolled in Medicare.

Does Medicaid cover Mounjaro?

State Medicaid programs cover Mounjaro for type 2 diabetes, usually with prior authorization. For weight loss, KFF counted 13 states covering GLP-1s as of January 2026 (Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, Wisconsin per SingleCare, May 21, 2026), and the list is shrinking: MassHealth ended coverage July 1, 2026 and Rhode Island ends it in October 2026.

How long does Medicare prior authorization take for Mounjaro?

Standard prior authorization decisions are required within 72 hours (3 business days). Expedited requests for urgent clinical situations must be decided within 24 hours. In practice, most approvals take 5 to 7 calendar days from submission to pharmacy notification.

Is compounded tirzepatide covered by Medicare?

No. Compounded medications cannot be billed to Medicare Part D. Medicare beneficiaries can pay cash for compounded tirzepatide, which had a month-one median of $299 across 14 telehealth providers in the FormBlends price index on September 3, 2026. Over a full year that is usually more than the $2,100 Part D out-of-pocket cap, so compounded mainly makes sense when Part D will not cover you at all.

What happens if I lose weight on Mounjaro while taking it for diabetes?

Weight loss is an expected therapeutic effect of Mounjaro when prescribed for diabetes. Medicare covers the medication for diabetes management, and weight loss as a secondary outcome doesn't affect coverage. The diagnosis code on the prescription determines coverage, not the clinical outcomes.

Can my doctor prescribe Mounjaro off-label for weight loss under Medicare?

Your doctor can prescribe Mounjaro off-label, but Medicare will deny coverage for any prescription with a weight-loss diagnosis code. You would need to pay the full cash price ($1,112.16 list per fill), use a compounded alternative, or ask about the Medicare GLP-1 Bridge, which since July 1, 2026 covers Wegovy, the Zepbound KwikPen and Foundayo at $50 a month for obesity in people without type 2 diabetes.

Does Medicare cover Mounjaro for type 2 diabetes in 2026?

Yes, through Part D, with prior authorization that documents type 2 diabetes. Under the 2026 standard benefit you pay up to a $615 deductible, then 25 percent coinsurance (about $278 per fill at Lilly's $1,112.16 list price), and $0 once your out-of-pocket spending on covered drugs reaches $2,100 (Medicare.gov, 2026 plan year). Prior authorization applied to nearly all Part D GLP-1 users in 2025 (JAMA, September 25, 2025).

Does SilverScript cover Mounjaro?

SilverScript is the Aetna and CVS Health brand of standalone Part D plan, and each SilverScript plan publishes its own formulary. We do not reproduce a specific plan's tier or copay here because those documents change every plan year. Enter your ZIP code and drug list in the Medicare Plan Finder at Medicare.gov, or read the plan's formulary PDF, and expect a prior authorization requiring a type 2 diabetes diagnosis; weight loss is not a covered use.

What is the Medicare GLP-1 Bridge, and does it cover Mounjaro?

The Bridge is a CMS program running July 1, 2026 through December 31, 2027 that pays for Wegovy (pen and pill), the Zepbound KwikPen and Foundayo at a $50 monthly copay for Part D enrollees who meet obesity criteria such as a BMI of 35 or higher (CMS provider page, August 6, 2026). Mounjaro is not on the list, and people with type 2 diabetes are excluded from the Bridge. The $50 copay does not count toward the $2,100 Part D cap.

I have Medicare with both type 2 diabetes and obesity. Which tirzepatide route applies to me?

Regular Part D coverage of Mounjaro for diabetes. CMS excludes anyone with type 2 diabetes from the GLP-1 Bridge, so the $50 Zepbound KwikPen route is closed to you (CMS, August 6, 2026; KFF, May 11, 2026). Your cost follows the 2026 Part D structure: deductible up to $615, 25 percent coinsurance, and $0 after $2,100 out of pocket. Weight loss while treating diabetes does not affect coverage.

Related guides

• Will Medicare Pay for Ozempic? Coverage Rules, Costs, and What Actually Gets Approved in 2026
• Will Medicare Pay for Zepbound in 2026? Coverage Rules, Costs, and What Actually Gets Approved
• Does Insurance Cover Tirzepatide in 2026? Coverage Rules, Denial Patterns, and What Actually Gets Approved
• Does Medicare Pay for Mounjaro in 2026? Coverage Rules, Part D Costs, and Real Copay Scenarios
• Does Medicare Cover Mounjaro for Type 2 Diabetes in 2026? Coverage Rules, Costs, and What Most Patients Don't Know
• Does Medicare Pay for Wegovy in 2026? Coverage Rules, Part D Gaps, and What You'll Actually Pay
• Tool: cost calculator

Sources

1. Social Security Administration. Social Security Act, Section 1862(a)(1)(A). 1965, amended 2003.
2. Centers for Medicare & Medicaid Services. Medicare Modernization Act of 2003. Federal Register. 2003.
3. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.
4. U.S. Congress. H.R. 1577, Treat and Reduce Obesity Act of 2026. 2026.
5. KFF. Recent trends in GLP-1 use and spending in Medicare, January 30, 2026. https://www.kff.org/medicare/recent-trends-in-glp-1-use-and-spending-in-medicare/
6. Penn LDI. Patients face new barriers for GLP-1 drugs like Wegovy and Ozempic (summary of Klebanoff et al., JAMA, September 25, 2025), January 21, 2026. https://ldi.upenn.edu/our-work/research-updates/patients-face-new-barriers-for-glp-1-drugs-like-wegovy-and-ozempic/
7. Removed September 2026: a JAMA Health Forum citation (2025;6(3):e250234) printed here earlier could not be located and the statistics attributed to it have been deleted from this article.
8. Medicare.gov. Part D costs, 2026 plan year (deductible up to $615, 25 percent coinsurance, $2,100 out-of-pocket cap). https://www.medicare.gov/health-drug-plans/part-d/basics/costs
9. U.S. Congress. Inflation Reduction Act of 2022, Part D Redesign Provisions. Public Law 117-169. 2022.
10. Eli Lilly. Mounjaro savings and coverage (current savings card terms and $1,112.16 list price), seen September 4, 2026. https://mounjaro.lilly.com/savings-coverage
11. U.S. Department of Health and Human Services, Office of Inspector General. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. Federal Register. 2014;79(218):65406-65409.
12. HHS ASPE. 2026 poverty guidelines. https://aspe.hhs.gov/poverty-guidelines
13. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge, information for providers, last updated August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
14. KFF. Medicaid coverage of and spending on GLP-1s, January 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
15. Medicare.gov. Part D costs for the 2026 plan year (deductible up to $615, 25 percent coinsurance, $2,100 out-of-pocket cap), seen September 5, 2026. https://www.medicare.gov/health-drug-plans/part-d/basics/costs
16. Medicare.gov. Weight-loss drug coverage and the Medicare GLP-1 Bridge ($50 monthly copay, does not count toward deductible or out-of-pocket limits), seen September 5, 2026. https://www.medicare.gov/coverage/weight-loss-drugs
17. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge: information for providers (July 1, 2026 to December 31, 2027; Wegovy, Zepbound KwikPen, Foundayo; BMI criteria; 72-hour decisions), last updated August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
18. KFF. What to know about the BALANCE model for GLP-1s in Medicare and Medicaid, May 11, 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
19. KFF. Recent trends in GLP-1 use and spending in Medicare, January 30, 2026. https://www.kff.org/medicare/recent-trends-in-glp-1-use-and-spending-in-medicare/
20. Penn LDI. Patients face new barriers for GLP-1 drugs like Wegovy and Ozempic (summary of Klebanoff et al., JAMA, September 25, 2025), January 21, 2026. https://ldi.upenn.edu/our-work/research-updates/patients-face-new-barriers-for-glp-1-drugs-like-wegovy-and-ozempic/
21. Eli Lilly. Mounjaro savings and coverage (list price $1,112.16 per fill; savings card $25 with $150, $300 and $450 caps, $1,950 a year, 13 fills, through December 31, 2026), seen September 4, 2026. https://mounjaro.lilly.com/savings-coverage
22. GoodRx. Does Medicare cover Mounjaro? (average retail price $1,351.69), seen September 5, 2026. https://www.goodrx.com/mounjaro/medicare-coverage
23. UnitedHealthcare. Prior authorization notification: diabetes agents, GLP-1 receptor agonists (A1C 6.5 percent or fasting glucose 126, 12-month authorization), effective July 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Notification-Diabetes-Agents-GLP1-Receptor-Agonists.pdf
24. KFF. Medicaid coverage of and spending on GLP-1s (13 states covered obesity use as of January 2026), January 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
25. healthinsurance.org. Does health insurance cover drugs used for weight loss such as Ozempic, Wegovy, Mounjaro and Zepbound? (employer survey, Medicaid exits, Marketplace data), updated August 20, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
26. SingleCare. How to get Wegovy covered by insurance (13 Medicaid states listed), May 21, 2026. https://www.singlecare.com/blog/how-to-get-wegovy-covered-by-insurance/
27. HHS Office of the Assistant Secretary for Planning and Evaluation. 2026 poverty guidelines (400 percent of the guideline is $63,840 for one person). https://aspe.hhs.gov/poverty-guidelines
28. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (adverse-event report counts as of May 31, 2026). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
29. FormBlends. Compounded GLP-1 Price Index methodology and current medians, data as of September 3, 2026. https://formblends.com/report/data/compounded-glp1-price-index

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.